On July 17, Tempus AI fell 5.17% in regular trading, trading at $54.214/share, with turnover of $123 million. The stock extended its recent weakness as multiple negative catalysts continued to pressure sentiment.

On the news front, Biovica International AB previously announced the termination of its collaboration agreement with Tempus AI, explicitly stating that the partnership failed to result in product commercialization or generate any revenue. Additionally, CEO and Chairman Eric P. Lefkofsky sold approximately 126,250 shares of Class A common stock through Rule 10b5-1 automatic trading plans at prices ranging from $54.82 to $59.59 per share. Freedom Capital Markets recently initiated coverage with a Hold rating and a $59 target price, which the current stock price has fallen significantly below.

Tempus AI operates as a healthcare technology company leveraging artificial intelligence for precision medicine, connecting laboratory results with patient clinical data to make diagnostic testing more intelligent and personalized. The company is scheduled to report Q2 earnings on July 30.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)